Xpert MTB/RIF Ultra

Home / Tests / TB & Emerging Infectious Diseases

Xpert® MTB/RIF Ultra

Enhanced performance in detecting drug-sensitive and -resistant Tuberculosis in less than 80 minutes

Test pack size(s)

50 Tests

GXMTB/RIF-ULTRA-50

Qty

Unit price

Subtotal

USD

10 Tests

GXMTB/RIF-ULTRA-10

Qty

Unit price

Subtotal

USD

Total

Error adding items to cart. If this error persists, please contact Digital Support

List name

Label

Having trouble? Contact Cepheid Digital Support

The Need

Each day, close to 4,400 people lose their lives to TB and nearly 30,000 people fall ill with this preventable and curable disease¹
Globally, diagnosis of TB and drug-resistant TB remains a challenge, with a third of people with TB and two-thirds of people with drug-resistant TB not being detected¹
Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission²

1 World Health Organization Tuberculosis Report 2023 - https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
2 Centers for Disease Control and Prevention—Guidelines for preventing the transmission of TB - https://www.cdc.gov/mmwr/preview/mmwrhtml/00001897.htm

The Solution

Xpert MTB/RIF Ultra provides fast and highly accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
Higher sensitivity, especially in smear-negative TB cases and among HIV-infected patients³
Simple three-step process with minimal hands-on time and results in ~80 min direct from sample
Designed to provide the most accurate MTB and Rifampicin detection utilizing multi-target and melt curves technology
Accurate detection of mixed infections

3 Aliasgar Esmail, et al, Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemicsetting https://researchonline.lshtm.ac.uk/id/eprint/4661245/1/1-s2.0-S1201971220301442-main.pdf

The Impact

Early detection of MTB and resistance to Rifampicin enables faster access to the most appropriate treatment for better patient outcomes⁴
Increased access to front-line testing with Xpert MTB/RIF Ultra as part of active case finding and management can help limit community transmission⁵
Superior performance of Xpert MTB/RIF Ultra versus smear microscopy enables more people with MTB infections to be detected and treated earlier⁴

4 Charkravorty S, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing - https://journals.asm.org/doi/10.1128/mbio.00812-17
5 Belén Saavedra, et al. Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding - https://erj.ersjournals.com/content/58/6/2100257